XSNX
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. The company specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. NovAccess Global Inc. was incorporated in 1997 and is headquartered in Chesterland, Ohio.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2024 Q3 | -0.02 | $0 | -$58,872 |
| 2024 Q2 | -0.02 | $0 | -$61,190 |
| 2023 Q1 | 0.06 | $0 | -$39,910 |
| 2023 Q4 | -0.08 | $0 | -$154,850 |
| 2023 Q3 | -0.04 | $0 | -$113,276 |
| 2023 Q2 | 0.02 | $0 | -$197,203 |
| 2022 Q1 | -0.14 | $0 | -$159,307 |
| 2022 Q4 | 0.13 | $0 | -$197,535 |